Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Designing proteins that work using recombinant technologies.

T J Graddis1, R L Remmele, J T McGrew

  • 1Dendreon Corporation, 3005 First Avenue, Seattle, WA 98121, USA.

Current Pharmaceutical Biotechnology
|December 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major histocompatibility complex class I-restricted presentation of protein antigens without prior intracellular processing.

Scandinavian journal of immunology·2003
Same author

Biophysical characterization of a soluble CD40 ligand (CD154) coiled-coil trimer: evidence of a reversible acid-denatured molten globule.

Archives of biochemistry and biophysics·2001
Same author

Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides.

Nature biotechnology·2000
Same author

Minimization of recombinant human Flt3 ligand aggregation at the Tm plateau: a matter of thermal reversibility.

Biochemistry·1999
Same author

Incorporation of an isoleucine zipper motif enhances the biological activity of soluble CD40L (CD154).

The Journal of biological chemistry·1998
Same author

Structure-function analysis of FLT3 ligand-FLT3 receptor interactions using a rapid functional screen.

The Journal of biological chemistry·1998

Protein engineering enhances therapeutic proteins by improving stability, efficacy, and reducing immune responses. Techniques like fusion proteins and site-specific modifications create novel treatments with better clinical performance.

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Drug Development

Background:

  • Therapeutic proteins are crucial in medicine, but often face challenges like immunogenicity and short half-lives.
  • Protein engineering offers solutions to overcome these limitations, enhancing therapeutic potential.

Purpose of the Study:

  • To review protein engineering techniques used to improve therapeutic protein properties.
  • To highlight methods for enhancing stability, efficacy, and reducing antigenicity of protein therapeutics.

Main Methods:

  • Review of rational design, directed evolution, DNA shuffling, and display technologies.
  • Analysis of engineered pegylation and glycosylation strategies.
  • Examination of fusion protein applications.

Related Experiment Videos

Main Results:

  • Protein engineering successfully yields candidates with reduced antigenicity and longer half-lives.
  • Site-specific modifications improve stability and clinical efficacy.
  • Fusion proteins enable novel therapeutic activities.

Conclusions:

  • Protein engineering is vital for developing advanced protein therapeutics.
  • Advanced techniques significantly enhance the stability and clinical performance of protein drugs.
  • Continued innovation in protein engineering promises more effective treatments.